neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice

Molecular and Cellular Biology

Volumn 17, Issue 6, 1997, Pages 3155-3163

  Li, Baolin ^a   Rosen, Jeffrey M ^b   Mcmenamin Balano, Jonathan ^a   Muller, William J ^c   Perkins, Archibald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; ONCOPROTEIN; PROTEIN P53;

ANEUPLOIDY; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSIS; ETIOLOGY; FEMALE; GENE AMPLIFICATION; MALE; MISSENSE MUTATION; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 0030946970     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.6.3155     Document Type: Article

References (76)

1. Ali I. U., G. Merlo, R. Gallahan, and R. Lidereau. 1989. The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. Oncogene 4:89-92.
2. Bayna, E. M., and J. M. Rosen. 1990. Tissue-specific, high level expression of the rat whey acidic protein gene in transgenic mice. Nucleic Acids Res. 18:2977-2985
3. Bienz, B., R. Zakut-Houri, D. Givol, and M. Oren. 1984. Analysis of the gene coding for the murine cellular tumor antigen p53. EMBO J. 3:2179-2183.
4. Blaydes, J. P., M. Shlumberger, D. Wynford-Thomas, and F. S. Wyllie. 1995. Interaction between p53 and TGF beta 1 in control of epithelial cell proliferation. Oncogene 10:307-317.
5. Caron de Fromental, C., and T. Soussi. 1992. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15.
6. Cheng, J., and M. Haas. 1990. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 10:5502-5509.
7. Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462.
8. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
9. Crawford, L., and P. Lamb. 1986. Characterization of the human p53 gene. Mol. Cell. Biol. 6:1379-1385.
10. Davidoff, A. M., P. A. Humphrey, J. D. Iglehart, and J. R. Marks. 1991. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. USA 88:5006-5010.
11. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. K. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42-46.
12. Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature 312:646-649.
13. Ewen, M. E., C. J. Oliver, H. K. Sluss, S. J. Miller, and D. S. Peeper. 1995. p53-dependent repression of cdk4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 9:204-217.
14. Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093.
15. Franch, H. A., J. A. Shay, R. J. Alpern, and P. A. Preisig. 1995. Involvement of pRB family in TGF beta-dependent epithelial cell hypertrophy. J. Cell Biol. 129:245-254.
16. Fusakawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747.
17. Gerwin, B. I., E. Spillare, K. Forrester, T. A. Lehman, J. Kispert, J. A. Welsh, A. M. A. Pfeifer, J. F. Lechner, S. J. Baker, B. Vogelstein, and C. C. Harris. 1992. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 89:2759-2763.
18. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 37:88-91.
19. Greenhalgh, D. A., X.-J. Wang, L. A. Donehower, and D. R. Roop. 1996. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 56:4413-4423.
20. Guy, S. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89:10578-10582.
21. Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P. Pantazis, B. C. Giovanella, M. A. Tainsky, A. Bradley, and L. A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467.
22. Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L. A. Donehower. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305-311.
23. Hedley, D. W., M. L. Friedlander, I. W. Taylor, C. A. Rugg, and E. A. Musgrove. 1983. Method for analysis of cellular DNA content of parafin-embedded pathological material using flow cytometry. J. Histochem. Cytochem. 31:1333-1335.
24. Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein, and A. J. Levine. 1990. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1:571-580.
25. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
26. Horak, E., K. Smith, L. Bromley, S. Lejeune, M. Greenall, D. Lane, and A. L. Harris. 1991. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6:2277-2284.
27. Hsiao, M. J. Low, E. Dorn, D. Ku, P. Pattengale, J. Yeargin, and M. Haas. 1994. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145:702-714.
28. Humphreys, R. C., M. Krajewska, S. Krnacik, R. Jaeger, H. Weiher, S. Krajewski, J. C. Reed, and J. M. Rosen. 1996. Apoptosis in the terminal end bud of the murine mammary gland: a mechanism of ductal morphogenesis. Development. 122:4013-1022.
29. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta Rev. Cancer 1198:16.1-184
30. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
31. Kern, S. E., K. W. Kinzler, S. J. Baker, J. M. Nigro, V. Rotter, A. J. Levine, P. Friedman, C. Prives, and B. Vogelstein. 1991. Mutated p53 binds DNA abnormally in vitro. Oncogene 6:131-136.
32. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-832.
33. Kieser, A., H. A. Weich, G. Brandner, D. Marme, and W. Kolch. 1994. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969.
34. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
35. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
36. Kumar, R., D. Medina, and S. Sukumar. 1990. Activation of H-Ras oncogene in preneoplastic mouse mammary tissue. Oncogene 5:1271-1277.
37. Lee, E. Y.-H., H. To, J. Y. Shew, R. Bookstein, P. Scully, and W.-H. Lee. 1988. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221.
38. Lee, K.-F., F. J. DeMayo, S. H. Aliee, and J. M. Rosen. 1988. Tissue-specific expression of the rat beta-casein gene in transgenic mice. Nucleic Acids Res. 16:1027-1041.
39. Li, B., F. S. Kittrell, D. Medina, and J. M. Rosen. 1995. Delay of dimethyl-benz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Mol. Carcinog. 13:75-83.
40. Arg-Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Differ. 5:711-721.
41. Li, B., D. Medina, and J. M. Rosen. Unpublished data.
42. Li, B., R. Murphy, R. Laucirica, F. S. Kittrell, D. Medina, and J. M. Rosen. Unpublished data.
43. Li, M., J. Hu, K. Heermeier, L. Henninghausen, and P. Furth. 1996. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. Cell Growth Differ. 7:13-20.
44. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
45. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
46. Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935-944.
47. Medina, D. 1974. Mammary tumorigenesis in chemical carcinogen-treated mice. I. Incidence in Balb-c and C57BL mice. J. Natl. Cancer Inst 53:213-221.
48. Metz, T., A. W. Harris, and J. M. Adams. 1995. Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell 82:29-36.
49. Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
50. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell 80:293-299.
51. Muller, W. J., et al. Unpublished results.
52. Muller, W. J., C. L. Arteaga, S. K. Muthuswamy, P. M. Siegel, M. A. Webster, R. D. Cardiff, K. S. Meise, F. Li, S. A. Halter, and R. J. Coffey. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 16:5726-5736.
53. Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
54. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708.
55. Ozbun, M. A., and J. S. Butel. 1995. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res. 66:71-141.
56. Pittius, C. W., L. Sankaran, Y. J. Topper, and L. Hennighausen. 1988. Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter i transgenic mice. Mol. Endocrinol. 2:1027-1032.
57. Ponchel, F., A. Puisieux, E. Tabone, J. P. Michot, G. Froschl, A. Morel, T. Frebourg, B. Fontaniere, F. Oberhammer, and M. Ozturk. 1994. Hepatocarcinoma-spccific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res 54:2064-2068.
58. Prosser, J., A. M. Thompson, G. Cranson, and H. J. Evans. 1990. Evidence that p53 behaves as a tumour suppressor gene in sporatic breast tumours. Oncogene 5:1573-1579.
59. Purdie, C., D. J. Harrison, A. Peter, L. Dobbie, S. White, S. E. M. Howie, D. M. Salter, C. C. Bird, A. H. Wyllie, M. L. Hooper, and A. R. Clarke. 1994. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603-609.
60. Reiss, M., V. F. Vellucci, and Z. Zhou. 1993. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res. 53:899-904.
61. Rosen, N., J. B. Bolen, A. M. Schwartz, P. Cohen, V. DeSeau, and M. A. Israel. 1986. Analysis of pp60 c-src protein kinase activity in human tumor cell lines and tissues. J. Biol. Chem. 261:13754-13759.
62. Rovinski, B., and S. Benchimol. 1988. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2:445-452.
63. Sabbatini, P., J. Lin, A. J. Levine, and E. White. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9:2184-2192.
64. Siegel, P. M., D. L. Dankort, W. R. Hardy, and W. J. Muller. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068-7077.
65. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and R. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 235:177-182.
66. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. C. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udore, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/ncu protooncogene in human breast and ovarian cancer. Science 244:707-712.
67. Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
68. Takahashi, T., B. Eitzman, and N. L. Bessert. 1994. Transforming growth factor b1, b2, and b3 messenger RNA and protein expression in mouse uterus and vagina during estrogen-induced growth: a comparison to other estrogen-regulated genes. Cell Growth Differ. 5:919-935.
69. Tsukada, T., Y. Tomooka, S. Takai, Y. Ueda, S. Nishikawa, T. Yagi, T. Tokunaga, N. Takeda, Y. Suda, S. Abe, I. Matsuo, Y. Ikawa, and S. Aizawa. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8:3313-3322.
70. Varley, J. M., W. J. Brammar, D. P. Lane, J. E. Swallow, C. Dolan, and R. A. Walker. 1991. Loss of chromosome 17p 13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413-421.
71. Waldman, T., C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716.
72. Wang, X.-J., et al. Personal communication.
73. Williams, A. C., S. J. Browne, A. M. Manning, P. Daffada, T. J. Collard, and C. Paraskeva. 1994. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1. Oncogene 9:1479-1485.
74. Wyllie, F. S., T. Dawson, J. A. Bond, P. Goretzki, S. Game, S. Prime, and D. Wynford-Thomas. 1991. Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation. Mol. Cell. Endocrinol. 76:13-21.
75. Yamamoto, M., Y. Maehara, Y. Sakaguchi, T. Kusumoto, Y. Ichiyoshi, and K. Sugimachi. 1996. Transforming growth factor-beta 1 induces apoptosis in gastric cancer cells through a p53-independent pathway. Cancer 77:1628-1633.
76. Yonish-Rouach, E., D. Resnitsky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wildtype p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345-347.